SANOFI80 Stock Price and Chart — SET:SANOFI80

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Sanofi is being investigated by Bronstein, Gewirtz & Grossman, LLC after mixed Phase 3 results for itepekimab, leading to a 5.7% drop in its ADRs on May 30, 2025.

Sanofi signed a Memorandum of Understanding with Abu Dhabi's Department of Health to boost global vaccine development, leveraging the region's health-tech ecosystem and research infrastructure.

Analyze the impact Analyze the impact

About SANOFI

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.